Bank of America’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-330,000
Closed -$33.1M 8433
2025
Q3
$33.1M Buy
330,000
+80,000
+32% +$7.21M ﹤0.01% 2118
2025
Q2
$20.7M Sell
250,000
-387,200
-61% -$30.9M ﹤0.01% 2521
2025
Q1
$51.7M Sell
637,200
-622,800
-49% -$55.7M ﹤0.01% 1551
2024
Q4
$113M Buy
1,260,000
+510,000
+68% +$49.4M 0.01% 955
2024
Q3
$74.1M Sell
750,000
-727,600
-49% -$71.5M 0.01% 1263
2024
Q2
$137M Sell
1,477,600
-564,100
-28% -$50.6M 0.01% 856
2024
Q1
$194M Buy
2,041,700
+673,400
+49% +$62.5M 0.02% 702
2023
Q4
$122M Buy
1,368,300
+200,800
+17% +$14.9M 0.01% 855
2023
Q3
$85.3M Sell
1,167,500
-2,027,300
-63% -$162M 0.01% 971
2023
Q2
$266M Buy
3,194,800
+2,184,900
+216% +$183M 0.03% 502
2023
Q1
$77M Buy
1,009,900
+75,000
+8% +$6.22M 0.01% 1090
2022
Q4
$77.6M Buy
934,900
+234,200
+33% +$19M 0.01% 1028
2022
Q3
$55.6M Sell
700,700
-399,300
-36% -$33.7M 0.01% 1188
2022
Q2
$81.7M Buy
1,100,000
+514,700
+88% +$38.6M 0.01% 993
2022
Q1
$52.6M Sell
585,300
-933,500
-61% -$86.2M 0.01% 1330
2021
Q4
$170M Buy
1,518,800
+1,264,600
+497% +$153M 0.02% 746
2021
Q3
$32M Sell
254,200
-629,200
-71% -$81M ﹤0.01% 1719
2021
Q2
$120M Buy
883,400
+873,000
+8,394% +$115M 0.01% 857
2021
Q1
$1.41M Sell
10,400
-667,600
-98% -$100M ﹤0.01% 4533
2020
Q4
$95.4M Buy
678,000
+331,700
+96% +$42.5M 0.01% 820
2020
Q3
$38.6M Buy
346,300
+21,300
+7% +$2.39M 0.01% 1236
2020
Q2
$36.4M Sell
325,000
-45,200
-12% -$4.45M 0.01% 1196
2020
Q1
$28.7M Buy
+370,200
New +$32.8M 0.01% 1268
2019
Q4
Sell
-957,000
Closed -$73M 7442
2019
Q3
$73M Buy
957,000
+765,200
+399% +$63.6M 0.01% 903
2019
Q2
$16.8M Sell
191,800
-188,000
-49% -$16M ﹤0.01% 2025
2019
Q1
$34.4M Sell
379,800
-440,200
-54% -$37.4M 0.01% 1391
2018
Q4
$58.8M Buy
820,000
+683,000
+499% +$55M 0.01% 910
2018
Q3
$13.1M Sell
137,000
-699,500
-84% -$67.8M ﹤0.01% 2190
2018
Q2
$79.6M Buy
836,500
+830,100
+12,970% +$76.3M 0.01% 798
2018
Q1
$561K Sell
6,400
-1,108,200
-99% -$101M ﹤0.01% 4741
2017
Q4
$94.6M Buy
1,114,600
+1,053,400
+1,721% +$88.2M 0.02% 757
2017
Q3
$5.3M Buy
61,200
+59,200
+2,960% +$4.75M ﹤0.01% 3129
2017
Q2
$154K Sell
2,000
-753,900
-100% -$53.5M ﹤0.01% 5426
2017
Q1
$52.4M Buy
755,900
+659,700
+686% +$44.3M 0.01% 1013
2016
Q4
$5.69M Buy
96,200
+96,000
+48,000% +$5.93M ﹤0.01% 2808
2016
Q3
$13K Sell
200
-400
-67% -$24.7K ﹤0.01% 6299
2016
Q2
$32K Sell
600
-202,800
-100% -$11.1M ﹤0.01% 6038
2016
Q1
$10.5M Buy
203,400
+33,500
+20% +$1.74M ﹤0.01% 2102
2015
Q4
$11.9M Sell
169,900
-100,300
-37% -$6.84M ﹤0.01% 2112
2015
Q3
$16.8M Buy
270,200
+120,200
+80% +$9.47M ﹤0.01% 1752
2015
Q2
$12.6M Buy
+150,000
New +$11.7M ﹤0.01% 1734
2014
Q3
Sell
-22,500
Closed -$1.16M 8201
2014
Q2
$1.16M Buy
+22,500
New +$1.01M ﹤0.01% 3869

Other funds holding XBI

Bank of America's XBI Position: Q1 2026 in Review

Bank of America increased its State Street SPDR S&P Biotech ETF (XBI) stake by 13% in Q1 2026, buying an estimated $212M and bringing the position to 14,518,027 shares worth $1.85B. The position accounts for 0.14% of the portfolio, ranked #161.

Bank of America first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Bank of America held 14,518,027 shares of State Street SPDR S&P Biotech ETF worth $1.85B as of Q1 2026.
  • Bank of America bought 1,700,851 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $212M.
  • State Street SPDR S&P Biotech ETF made up 0.14% of Bank of America's portfolio in Q1 2026, its #161 holding.
  • Bank of America first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
  • 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.